A novel targeted nucleic acid drug targeting ARL4C inhibits the expression of ARL4C in colorectal cancer cells, and ultimately reduces the proliferation and migration of cancer cells (Harada et al., 2019). This evidence concerns the gene ARL4C and colorectal cancer.